The monitoring of chimerism has become a routine diagnostic instrument at centers performing allogeneic stem cell or bone marrow transplantation. Despite the widespread use of molecular techniques permitting the assessment and the surveillance of donor-and recipient-derived hemopoiesis, there have been no international efforts to standardize the technical approaches, and to provide a basis for the comparison of diagnostic results. We believe that in this rapidly growing field there is a need for standardization directed towards optimum diagnostic support for clinical decision making.
The Debate Round- In this issue, Leukemia presents new contributions to the Debate illustrating some of the ideas which we hope will stimulate discussion of both technical and clinical aspects of chimerism testing. The first paper (Shimoni et al) is a review addressing the role of chimerism testing in patients undergoing nonmyeloablative stem cell transplantation. In the second paper (Mattsson et al) , the authors show the use of lineage-specific chimerism testing for prediction of relapse in patients transplanted for treatment of acute myeloid leukemia and myelodysplastic syndrome. The third contribution (González et al) is a commentary discussing the clinical role of chimerism testing after allogeneic stem cell transplantation in adult patients. The fourth contribution (Klingebiel et al) addresses the clinical and ethical problems of prospective vs historical trials on chimerism testing in pediatric patients. In view of the fact that the issues raised are controversial, three experts in the field (M Lawler, A Biondi and A Balduzzi) comment on the views presented by Klingebiel and his colleagues. We hope that these contributions will stimulate further discussion of the important issues raised.
In the technical part of the debate, we would like to discuss different methodological approaches, and to extract the best of the currently available techniques as a basis for optimized diagnostic strategies. Together, we will try to define appropriate sensitivity standards and adequate controls for quality-assured molecular diagnosis. Based on the results of this debate and the current state of the art, we would like to establish generally accepted standards for chimerism testing in the light of the possible therapeutic implications. A consensus will not be forced, however, and it is understood that standards need to be revised. In the clinically oriented part of the debate, we would like to discuss the optimum timing of chimerism analysis, and the therapy options inferable from molecular monitoring in different transplant settings.
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Nicole Muller-Bérat, MD, PhD Guest Editor Editor-in Chief Contributions to the Debate should be labeled 'Round Table on Chimerism Testing', and sent to the Leukemia office in Paris which will transmit the manuscripts to the guest Editor of the Debate (T Lion). There is no limitation to the number of participants in the Debate. The contributions can be short notes of up to 2500 words with a few references, regular papers or editorials.
